You browser is out of date and some functionality on this site may be not supported.
Please consider upgrading to the latest version of your browser for the best possible experience.
Kindly note that this website is not compatible with this browser. Some features may not work. Inconvenience regretted.
Early detection and screening of SCID-SMA is a vital health goal for infants
Severe combined immunodeficiency (SCID) is a group of rare inherited disorders caused by mutations in various genes involved in the development and function of immune cells that fight infection. SCID is characterized by T- and B-cell lymphopenias.
Early detection of Severe Combined Immunodeficiency (SCID) and Spinal Muscular Atrophy (SMA) is vital for prevention of permanent disabilities or mortality of neonates. SCID is a congenital genetic disorder that causes life-threatening problems by supressing the immune system. This immunodeficiency occurs due to the lack of T cells, B cells and NK cells count. SMA is autosomal recessive disorder that causes neuromuscular disorder. This disorder is characterized by progressive degeneration and irreversible loss of lower motor neurons.
Spinal Muscular Atrophy (SMA) is the second most common autosomal recessive disorder which is characterized by the loss of motor function and muscle mass due to degeneration of neurons in the spinal cord and the brain stem.